High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma

An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

(2014) Soo Jeong Nam et al.   LEUKEMIA & LYMPHOMA

The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer

(2012) Sofia Edin et al.   PLoS One

Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group

(2011) Naoki Wada et al.   HISTOPATHOLOGY

Tumor-Associated Macrophages in the Cutaneous SCC Microenvironment Are Heterogeneously Activated

(2011) Julia S. Pettersen et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma

(2011) Qi-chun Cai et al.   MEDICAL ONCOLOGY

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

(2010) Junliang Ma et al.   BMC CANCER

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of CD68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis

(2008) Sverker Hasselblom et al.   PATHOLOGY INTERNATIONAL